In addition to directly inhibiting BTK, ibrutinib also modulates the immune system and alters the CLL microenvironment by blocking multiple signaling pathways and inducing cell apoptosis [7]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.